ArticleFrontiers in medicine2026
Clinical phenotype and GNPTAB gene mutation spectrum analysis of Chinese patients with mucolipidosis type II α/β.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Mucolipidosis type II α/β (ML II α/β) is a rare autosomal recessive lysosomal storage disorder caused by mutations in the Methods: Whole-exome sequencing (WES) was performed on a new proband, and a comprehensive literature review was conducted, summarizing a total of 56 Chinese cases (including 1 new case). Results: All patients presented with skeletal deformities (100%), 96.4% had coarse facial features, 94.6% had developmental delay, and the median age at diagnosis was 17.5 months. The new proband carried compound heterozygous non-sense mutations NM_024312.4:c.2455G>T (p.Glu819*) and NM_024312.4:c.1123C>T (p.Arg375*) and died of respiratory failure at 27 months of age. Notably, NM_024312.4:c.1090C>T (p.Arg364*) was the most common mutation (found in 39.3% of patients), associated with typical skeletal abnormalities and early death. Cardiac abnormalities (16.1%) and pulmonary complications (12.5%) were common comorbidities. Conclusion: This study identified a unique mutational hotspot in Chinese patients with ML II α/β and revealed a severe phenotype with poor prognosis, primarily resulting in death from respiratory failure. These findings are beneficial for clinical diagnosis, genetic counseling, and targeted molecular screening of this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.